From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
Recurrent HGNMIBC, n° of patients (%)
6 (23.1%)
TaG3
1 (3.8%)
T1G3
2 (7.7%)
Cis
Ta/T1G3 + Cis
Evidence of MIBC, n° of patients (%)
4 (15.4%)
T2
3 (11.5%)
T4